Neuroblastoma is one of the most common cancers in children and has limited treatment options. In a new study, researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with 131I-metaiodobenzylguanidine (131I-MIBG) and discovered a favorable prognosis in these patients.
Neuroblastoma forms in organs that embryologically originate from nerve tissue, such as in the adrenal glands or in the nervous system. It is the most common solid tumor that occurs in children in areas outside of the head. Neuroblastoma patients can be divided into three distinct risk groups based on the child's age, cancer stage, and the morphology of the cancer. While children in the low and intermediate risk groups can often be cured by surgery or chemotherapy and thus have favorable outcomes, children in the high risk group have to undergo more aggressive chemotherapy, stem cell transplantation or radiation with limited success and overall poor prognosis.
To watch the webinar please visit:
Source: KANAZAWA UNIVERSITY